Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

Nature

Volumn 450, Issue 7170, 2007, Pages 741-744

  Zhang, Xuewu ^a,d   Pickin, Kerry A ^b   Bose, Ron ^b,e   Jura, Natalia ^a   Cole, Philip A ^b   Kuriyan, John ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN INDUCED GENE 6 PROTEIN; UNCLASSIFIED DRUG;

CYTOPLASM; ENZYME ACTIVITY; INHIBITION; PROTEIN;

ANIMAL CELL; ARTICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN;

EID: 36749011864     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05998     Document Type: Article

References (22)

1. Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341-354 (2005).
2. Zhang, X. et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 (2006).
3. Hackel, P. O., Gishizky, M. & Ullrich, A. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol. Chem. 382, 1649-1662 (2001).
4. Xu, D., Makkinje, A. & Kyriakis, J. M. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J. Biol. Chem. 280, 2924-2933 (2005).
5. Fiorentino, L. et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol. Cell. Biol. 20, 7735-7750 (2000).
6. Wood, E. R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
7. Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313-320 (1995).
8. Ballaro, C. et al. Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype. EMBO Rep. 6, 755-761 (2005).
9. Ferby, I. et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nature Med. 12, 568-573 (2006).
10. Zhang, Y. W. et al. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 26, 269-276 (2007).
11. Shen, F. et al. Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol. Biol. Cell 18, 732-742 (2007).
12. Anastasi, S. et al. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22, 4221-4234 (2003).
13. Anastasi, S. et al. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene advanced online publication doi:10.1038/sj.onc.1210590 (18 June 2007).
14. Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265-46272 (2002).
15. Depetris, R. S. et al. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol. Cell 20, 325-333 (2005).
16. Lei, M., Robinson, M. A. & Harrison, S. C. The active conformation of the PAK1 kinase domain. Structure 13, 769-778 (2005).
17. Reynolds, A. R. et al. EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nature Cell Biol. 5, 447-453 (2003).
18. Ichinose, J., Murata, M., Yanagida, T. & Sako, Y. EGF signalling amplification induced by dynamic clustering of EGFR. Biochem. Biophys. Res. Commun. 324, 1143-1149 (2004).
19. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
20. Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
21. Conti, E. & Kuriyan, J. Crystallographic analysis of the specific yet versatile recognition of distinct nuclear localization signals by karyopherin α. Structure 8, 329-338 (2000).
22. Wedegaertner, P. B. & Gill, G. N. Activation of the purified protein tyrosine kinase domain of the epidermal growth factor receptor. J. Biol. Chem. 264, 11346-11353 (1989).